AlphaMark Advisors LLC Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AlphaMark Advisors LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,741 shares of the biopharmaceutical company’s stock after selling 84 shares during the period. AlphaMark Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,676,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock worth $7,762,577,000 after purchasing an additional 39,780 shares in the last quarter. Capital World Investors boosted its position in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after purchasing an additional 23,146 shares in the last quarter. Putnam Investments LLC boosted its position in shares of Regeneron Pharmaceuticals by 2.1% during the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after purchasing an additional 24,329 shares in the last quarter. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $932,571,000. Finally, Morgan Stanley boosted its position in shares of Regeneron Pharmaceuticals by 2.7% during the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock worth $799,061,000 after purchasing an additional 25,792 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Cantor Fitzgerald reiterated a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, May 3rd. Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. Argus boosted their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. JPMorgan Chase & Co. boosted their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Monday, June 17th. Finally, Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,027.55.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the sale, the chief executive officer now owns 408,200 shares in the company, valued at approximately $399,729,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,347,256.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The disclosure for this sale can be found here. In the last quarter, insiders sold 61,971 shares of company stock worth $61,217,654. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ REGN traded up $5.99 on Monday, reaching $1,057.02. 383,191 shares of the company traded hands, compared to its average volume of 479,454. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $688.52 and a fifty-two week high of $1,081.17. The company has a 50 day moving average of $984.27 and a 200 day moving average of $951.53. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $116.47 billion, a PE ratio of 31.23, a P/E/G ratio of 2.17 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The firm had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.